Key Highlights

  • Net loss for the third quarter ended September 30, 2026 was USD 11.0 million, or USD 0.46 per share, narrower than the USD 11.9 million, or USD 0.64 per share, reported a year earlier.
  • Cash, cash equivalents and marketable securities totaled USD 82.9 million at September 30, 2026, and management said the funds should cover operating and Capital needs into 2028.
  • Research and development expense fell to USD 8.3 million in the quarter from USD 9.1 million, while general and administrative expense eased to USD 3.5 million from USD 3.6 million.
  • Nine-month net cash used in Operating Activities was USD 33.2 million versus USD 31.3 million, and the company has sold no shares under its USD 100.0 million at-the-market program.

A Narrower Loss as Manufacturing Spend Falls

Kalaris Therapeutics (NASDAQ:KLRS) filed its Quarterly Report for the period ended September 30, 2026 on November 10, 2026. The company has no approved products and no revenue, so the result is a cost story. Net loss was USD 11.0 million against USD 11.9 million, and total operating expenses dropped to USD 11.8 million from USD 12.7 million. Research and Development fell USD 0.8 million, driven by a USD 1.5 million decline in manufacturing and process development, partly offset by USD 0.6 million more in clinical research costs as additional trial sites opened. Other income, mostly interest on Money Market funds and Treasury securities, was USD 0.8 million in both periods.

Nine-Month Costs, Cash Burn and the TH103 Program

Over nine months, the net loss was USD 33.4 million, flat with the prior year, and loss per share improved to USD 1.40 from USD 2.41 because more shares were outstanding. Research and development rose to USD 24.9 million from USD 23.6 million as clinical spending grew USD 3.9 million, offset by a USD 2.8 million manufacturing decline. The lead candidate, TH103, is a VEGF-trap protein being studied in neovascular, or wet, age-related macular degeneration. The company reported positive additional Phase 1a data in July 2026 and is running a Phase 1b/2 dose-finding study planned for about 60 to 80 patients. Cash and equivalents stood at USD 47.4 million, with USD 35.5 million in short-term marketable securities.

Funding Options and Unremediated Control Weaknesses

The company has a shelf registration for up to USD 350.0 million, effective April 13, 2026, and an at-the-market program for up to USD 100.0 million of common stock, under which nothing has been sold. Because it has no revenue, further capital would likely come from equity, and issuing shares dilutes existing holders. The filing also says disclosure controls were not effective because previously reported material weaknesses in internal control were not fully remediated. Remediation steps include a new enterprise resource planning system, added accounting staff and a Chief Financial Officer hired in July 2026. The company also noted that clinical outcomes are uncertain and that it expects losses to continue for the foreseeable future.

Where Things Stand

A USD 82.9 million balance reaches into 2028 on management's own estimate, which is a view the filing itself says may prove wrong. Kalaris Therapeutics (NASDAQ:KLRS) trimmed its quarterly loss to USD 11.0 million, but nine-month cash used in operations rose to USD 33.2 million and spending is expected to increase as TH103 advances. The filing gives no price move or consensus figures, so the quarter reads mainly as a runway update. Next markers are Phase 1b/2 progress, any use of the at-the-market program and the remediation of the control weaknesses.